Comparative studies of prostate cancer in Japan versus the United States: A review

Urologic Oncology

Volumn 5, Issue 6, 2000, Pages 274-283

  Watanabe, Masatoshi ^a   Nakayama, Tsuyoshi ^a   Shiraishi, Taizo ^a   Stemmermann, Grant N ^b   Yatani, Ryuichi ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Ethnic racial difference; Genetic alteration; Polymorphism; Prostate cancer

Indexed keywords

ANDROGEN; ESTRADIOL; ESTROGEN; PROGESTERONE; STEROID 5ALPHA REDUCTASE; VITAMIN D RECEPTOR;

ADULT; AGED; DIETARY INTAKE; ETHNIC GROUP; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; IMMIGRANT; JAPAN; MAJOR CLINICAL STUDY; MALE; MALE GENITAL TRACT CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; REVIEW; SOMATIC MUTATION; UNITED STATES;

EID: 0033801323     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(00)00092-2     Document Type: Review

References (109)

1. Gittes R.F. Carcinoma of the prostate. New Engl J Med. 324:1991;236-245.
2. Boyle P., Maisonneuve P., Napalkov P. Geographical and temporal patterns of incidence and mortality from prostate cancer. Urology. 46:1995;47-55.
3. Merrill R.M., Brawley O.W. Prostate cancer incidence and mortality rates among whites and black men. Epidemiology. 8:1997;126-131.
4. Merrill R.M., Potosky A.L., Feuer E.J. Changing trends in U.S. prostate cancer incidence rates. J Natl Cancer Inst. 88:1996;1683-1685.
5. Dun J.E. Jr. Breast cancer among American Japanese in the San Francisco Bay area. Natl Cancer Inst Monogr. 47:1977;157-160.
6. Boyle P., Maisonneuve P., Napalkov P. Incidence of prostate cancer will double by the year 2030. the argument for Eur Urol. 29(suppl 2):1996;3-9.
7. Kakizoe T., Nakamura Y., Segami K.et al. Cancer statistics in Japan-1997. 1998;Foundation for Promotion of Cancer Research, Tokyo.
8. Haenszel W., Kurihara M. Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst. 40:1968;43-68.
9. Moradi T., Delfino R.J., Bergstom S.R., Yu E.S., Adami H.O., Yuen J. Cancer risk among Scandinavian immigrants in the US and Scandinavian residents compared with US whites, 1973-89. Eur J Cancer Prev. 7:1998;117-125.
10. Geddes M., Balzi D., Buiatti E., Khlat M., Parkin D. Cancer in Italian migrants. Cancer Causes Control. 2:1991;133-140.
11. King H., Locke F.B. Cancer mortality among Chinese in the United States. J Natl Cancer Inst. 65:1980;1141-1148.
12. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J. Cancer incidence in five continents. Vol. VII. Lyon, France: IARC Scientific Publication 143, 1997.
13. Shimizu H., Ross R.K., Bernstein L., Yatani R., Henderson B.E., Mack T.M. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer. 63:1991;963-966.
14. Cook L.S., Goldoft M., Schwartz S.M., Weiss N.S. Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. J Urol. 161:1999;152-155.
15. Mettlin C. Recent developments in the epidemiology of prostate cancer. Eur J Cancer. 33:1997;340-347.
16. Denis L., Morton M.S., Griffiths K. Diet and its preventive role in prostatic disease. Eur Urol. 35:1999;377-387.
17. Kolonel L.N. Nutrition and prostate cancer. Cancer Causes Control. 7:1996;83-94.
18. Ohno Y., Yoshida O., Oishi K., Okada K., Yamabe H., Schroeder F.H. Dietary β-carotene and cancer of the prostate. a case-control study in Kyoto, Japan Cancer Res. 48:1988;1331-1336.
19. Severson R.K., Nomura A.M.Y., Grove J.S., Stemmermann G.N. A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res. 49:1989;1857-1860.
20. Whittemore A.S., Kolonel L.N., Wu A.H.et al. Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst. 87:1995;652-661.
21. Tominaga S., Kuroishi T. An ecological study on diet/nutrition and cancer in Japan. Int J Cancer. 10:1997;2-6.
22. Shirai T., Sano M., Tamano S.et al. The prostate. a target for carcinogenicity of 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine (PhIP) derived from cooked foods Cancer Res. 57:1997;195-198.
23. Wakabayashi K., Totsuka Y., Fukutome K., Oguri A., Ushiyama H., Sugimura T. Human exposure to mutagenic/carcinogenic heterocyclic amines and comutagenic beta-carbolines. Mutat Res. 376:1997;253-259.
24. Moyad M.A. Soy, disease and prostate cancer. Semin Urol Oncol. 17:1999;97-102.
25. Onozawa M., Kawamori T., Baba M.et al. Effects of a soybean isoflavone mixture on carcinogenesis in prostate and seminal vesicles of F344 rats. Jpn J Cancer Res. 90:1999;393-398.
26. Adlercreutz H., Markkanen H., Watanabe S. Plasma concentrations of phyto-oestrogens in Japanese men. Lancet. 342:1993;1209-1210.
27. Strom S.S., Yamamura Y., Duphoral C.M.et al. Phytoestrogen intake and prostate cancer. a case-control study using a new database Nutr Cancer. 33:1999;20-25.
28. Schottenfeld D., Fraumeni J.F. Jr. Cancer epidemiology and prevention. 1996;Oxford University Press, New York.
29. Nomura A.M.Y., Stemmermann G.N., Chyou P.H., Henderson B.E., Stanczyk F.Z. Serum androgens and prostate cancer. Cancer Epidemiol Biomarkers Prev. 5:1996;621-625.
30. Koivisto P., Kononen J., Palmberg C.et al. Androgen receptor gene amplification. a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer Cancer Res. 57:1997;314-319.
31. Akazaki K., Stemmermann G.N. Comparative study of latent carcinoma of the prostate among Japanese in Japan and Hawaii. J Natl Cancer Inst. 50:1973;1137-1144.
32. Sheldon C.A., Williams R.D., Fraley E.E. Incidental carcinoma of the prostate. a review of the litarature and critical reappraisal of classification J Urol. 124:1980;626-631.
33. Sakr W.A., Haas G.P., Cassin B.F., Pontes J.E., Crissman J.D. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol. 150:1993;379-385.
34. Yatani R., Kusano I., Shiraishi T., Hayashi T., Stemmermann G.N. Latent prostatic carcinoma. pathological and epidemiological aspects Jpn J Clin Oncol. 19:1989;319-326.
35. Akazaki K. Comparative studies on the prevalence of latent prostate cancer among Japanese, American and Colombian males. Director's Report, 1968/69. Naagoya, Japan: Aichi Cancer Center Research Institute, 1973.
36. Guileyardo J.M., Jonson W.D., Welsh R.A., Akazaki K., Correa P. Prevalence of latent prostate carcinoma in two US populations. J Natl Cancer Inst. 65:1980;311-316.
37. Yatani R., Chigusa I., Akazaki K., Stemmermann G.N., Welsh R.A., Correa P. Geographic pathology of latent prostatic carcinoma. Int J Cancer. 29:1982;611-616.
38. Yatani R., Shiraishi T., Nakakuki K.et al. Trends in frequency of latent prostate carcinoma in Japan from 1965-1979 to 1982-1986. J Natl Cancer Inst. 80:1988;683-687.
39. Yatani R. The initiation and progression of human prostate cancer. Geographic and molecular pathologic approach Proc Jpn Soc Pathol. 86:1997;47-62. (in Japanese).
40. Shiraishi T., Watanabe M., Matsura H., Kusano I., Yatani R., Stemmermann G.N. The frequency of latent prostatic carcinoma in young males. the Japanese experience In Vivo. 8:1994;445-448.
41. Shiraishi T, Ioshii SO, Watanabe M, et al. Geographic pathology of latent prostatic carcinoma: an international comparison. In: Imai K, Shimazaki J, Karr JP, editors. Fundamental approaches to the diagnosis and treatment of prostate cancer and BPH. Proceedings of the Fifth Tokyo Symposium. New York: Adenine Press, 1994.
42. Helpap B.G.T., Bostwick D.G., Montironi R. The significance of atypical adenomatous hyperplasia and prostatic intraepithelial neoplasia for the development of prostate carcinoma. Virchows Arch. 426:1995;425-434.
43. McNeal J.E., Haillot O., Yemoto C. Cell proliferation in dysplasia of the prostate. analysis by PCNA immunostaining Prostate. 27:1995;258-268.
44. Colombel M., Symmans F., Gil S.et al. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone refractory human prostate cancers. Am J Pathol. 143:1993;390-400.
45. Myers R.B., Grizzle W.E. Biomarker expression in prostatic intraepithelial neoplasia. Eur Urol. 30:1996;153-166.
46. Kovi J., Mostofi F.K. Atypical hyperplasia of prostate. Urology. 34(suppl 6):1989;23-27.
47. McNeal J.E., Bostwick D.G. Intraductal dysplasia. a premalignant lesion of the prostate Hum Pathol. 17:1986;64-71.
48. Billis A. Latent carcinoma and atypical lesions of prostate. Urology. 28:1986;324-329.
49. Troncoso P., Babaian R.J., Ro J.Y., Grignon D.J., von Eschenbach A.C., Ayala A.G. Prostatic intraepithelial neoplasia and invasive prostatic adenocarcinoma in cystoprostatectomy specimens. Urology. 34(suppl 6):1989;52-56.
50. Fujita M.Q., Shin M., Yasunaga Y.et al. Incidence of prostatic intra-epithelial neoplasia in Osaka, Japan. Int J Cancer. 73:1997;808-811.
51. Epstein J.I., Cho K.R., Quinn B.D. Relationship of severe dysplasia to stage A (incidental) adenocarcinoma of the prostate. Cancer. 65:1990;2321-2327.
52. Quinn B.D., Cho K.R., Epstein J.I. Relationship of severe dysplasia to stage B adenocarcinoma of prostate. Cancer. 65:1990;2328-2333.
53. Humphrey P.A., Frzier H.A., Paulson D.F., Vollmer R.T. Extent of severe dysplasia in the prostate is inversely related to pathologic stage. Mod Pathol. 5:1992;5A.
54. Sakr W.A., Grignon D.J., Haas G.P., Heilbrun L.K., Pontes J.E., Crissman J.D. Age and racial distribution of prostatic intraepithelial neoplasia. Eur Urol. 30:1996;138-144.
55. Minamoto T., Mai M., Ronai Z. Environmental factors as regulators and effectors of multistep carcinogenesis. Carcinogenesis. 20:1999;519-527.
56. Shibata A., Whittemore A.S. Genetic prediction to prostate cancer. possible explanations for ethnic differences in risk Prostate. 32:1997;65-72.
57. Narod S. Genetic epidemiology of prostate cancer. Biochim Biophys Acta. 1423:1998;F1-F2.
58. Vogelstein B., Fearon E.R., Hamilton S.R.et al. Genetic alterations during colorectal tumor development. New Engl J Med. 319:1988;525-532.
59. Lalani E.-N., Laniado M.E., Abel P.D. Molecular and cellular biology of prostate cancer. Cancer Metastasis Rev. 16:1997;29-66.
60. Barbacid M. ras genes. Annu Rev Biochem. 56:1987;779-827.
61. Peehl D.M., Wehner N., Stamey T.A. Activated Ki-ras oncogene in human prostatic adenocarcinoma. Prostate. 10:1987;281-289.
62. Carter B.S., Epstein J.I., Isaacs W.B. ras gene mutations in human prostate cancer. Cancer Res. 50:1990;6830-6832.
63. Gumerlock P.H., Poonamallee U.R., Meyers F.J., deVere White R.W. Activated ras alleles in human carcinoma of the prostate are rare. Cancer Res. 51:1991;1632-1637.
64. Moul J.W., Friedrichs P.A., Lance R.S., Theune S.M., Chang E.H. Infrequent RAS oncogene mutations in human prostate cancer. Prostate. 20:1992;327-338.
65. Anwar K., Nakakuki K., Shiraishi T., Naiki H., Yatani R., Inuzuka M. Presence of ras oncogene mutations and human papillomavirus DNA in human prostate carcinomas. Cancer Res. 52:1992;5991-5996.
66. Konishi N., Enomoto T., Buzard G., Ohshima M., Ward J.M., Rice J.M. K-ras activation and ras p21 expression in latent prostatic carcinoma in Japanese men. Cancer. 69:1992;2293-2299.
67. Watanabe M., Shiraishi T., Yatani R., Nomura A.M., Stemmermann G.N. International comparison on ras gene mutations in latent prostate carcinoma. Int J Cancer. 58:1994;174-178.
68. Suzuki H., Aida S., Akimoto S., Igarashi T., Yatani R., Shimazaki J. State of adenomatous polyposis coli gene and ras oncogenes in Japanese prostate cancer. Jpn J Cancer Res. 85:1994;847-852.
69. Konishi N., Hiasa Y., Tsuzuki T., Tao M., Enomoto T., Miller G.J. Comparison of ras activation in prostate carcinoma in Japanese and American men. Prostate. 30:1997;53-57.
70. Shiraishi T., Muneyuki T., Fukutome K.et al. Mutations of ras genes are relatively frequent in Japanese prostate cancers. pointing to genetic differences between populations Anticancer Res. 18:1998;2789-2792.
71. Lane D.P. Cancer, p53, guardian of the genome. Nature. 358:1992;15-16.
72. Konishi N., Cho M., Yamamoto K., Hiasa Y. Genetic changes in prostate cancer. Pathol Int. 47:1997;735-747.
73. Stapleton A.M., Timme T.L., Gousse A.E.et al. Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases. Clin Cancer Res. 3:1997;1389-1397.
74. Navone N.M., Labate M.E., Troncoso P.et al. p53 Mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. J Urol. 161:1999;304-308.
75. Greenblatt M.S., Bennett W.P., Hollstein M., Harris C.C. Mutations in the p53 tumor suppressor gene. Clues to cancer etiology and molecular pathogenesis Cancer Res. 54:1994;4855-4878.
76. Watanabe M., Ushijima T., Kakiuchi H.et al. p53 Gene mutations in human prostate cancers in Japan. different mutation spectra between Japan and western countries Jpn J Cancer Res. 85:1994;904-910.
77. Watanabe M., Fukutome K., Shiraishi T.et al. Differences in the p53 gene mutational spectra of prostate cancers between Japan and Western countries. Carcinogenesis. 18:1997;1355-1358.
78. Wilding G. The importance of steroid hormones in prostate cancer. Parker M.G. Growth regulation by nuclear hormone receptors. 1992;113-130 Cold Spring Harbor Laboratory Press, Plainview, NY.
79. Nomura A.M.Y., Kolonel L.N. Prostate cancer. a current perspective Epidemiol Rev. 13:1991;200-227.
80. Wilson J.D., Griffin J.E., Russell D.W. Steroid 5α-reductase deficiency. Endocrinol Rev. 14:1993;577-593.
81. Davis D.L., Russell D.W. Unusual length polymorphism in human steroid 5α-reductase type 2 gene (SRD5A2). Hum Mol Genet. 2:1993;820.
82. Riechardt J.K., Makridakis N., Henderson B.E., Yu M.C., Pike M.C., Ross R.K. Genetic variability of the human SRD5A2 gene. implications for prostate cancer risk Cancer Res. 55:1995;3973-3975.
83. Kantoff P.W., Febbo P.G., Giovannucci E.et al. A polymorphism of the 5 alpha-reductase gene and its association with prostate cancer. a case-control analysis Cancer Epidemiol Biomarkers Prev. 6:1997;189-192.
84. Ross R.K., Bernstein L., Lobo R.A.et al. 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet. 339:1992;887-889.
85. Veldscholte J., Ris-Stalpers C., Kuiper G.G.et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun. 173:1990;534-540.
86. Takahashi H., Furusato M., Allsbrook W.C. Jr. et al. Prevalence of androgen receptor gene mutations in latent prostatic carcinomas from Japanese men. Cancer Res. 55:1995;1621-1624.
87. Kantoff P., Giovannucci E., Brown M. The androgen receptor CAG repeat polymorphism and its relationship to prostate cancer. Biochim Biophys Acta. 1378:1998;C1-C5.
88. Chamberlain N.L., Driver E.D., Miesfeld R.L. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res. 22:1994;3181-3186.
89. Schoenberg M.P., Hakimi J.M., Wang S.et al. Microsatellite mutation (CAG24->18) in the androgen receptor gene in human prostate cancer. Biochem Biophys Res Commun. 198:1994;74-80.
90. Watanabe M., Ushijima T., Shiraishi T.et al. Genetic alterations of androgen receptor gene in Japanese human prostate cancer. Jpn J Clin Oncol. 27:1997;389-393.
91. Coetzee G.A., Ross R.K. Re. prostate cancer and the androgen receptor J Natl Cancer Inst. 86:1994;872-873.
92. Irvine R.A., Yu M.C., Ross R.K., Coetzee G.A. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res. 55:1995;1937-1940.
93. Stanford J.L., Just J.J., Gibbs M.et al. Polymorphic repeats in the androgen receptor gene. molecular markers of prostate cancer risk Cancer Res. 57:1997;1194-1198.
94. Watkins W.S., Bamshad M., Jorde L.B. Population genetics of trinucleotide repeat polymorphisms. Hum Mol Genet. 4:1995;1485-1491.
95. Peehl D.M., Skowronski R.J., Leung G.K., Wong S.T., Stamey T.A., Feldman D. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res. 54:1994;805-810.
96. Taylor J.A., Hirvonen A., Watson M., Pittman G., Mohler J.L., Bell D.A. Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res. 56:1996;4108-4110.
97. Ingles S.A., Ross R.K., Yu M.C.et al. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst. 89:1997;166-170.
98. Ingles S.A., Coetzee G.A., Ross R.K.et al. Association of prostate cancer with vitamin D receptor haplotypes in African-Americans. Cancer Res. 58:1998;1620-1623.
99. Ma J., Stampfer M.J., Gann P.H.et al. Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. Cancer Epidemiol Biomarkers Prev. 7:1998;385-390.
100. Ingles S.A., Haile R.W., Henderson B.E.et al. Strength of linkage disequilibrium between two vitamin D receptor markers in five ethnic groups. implication for association studies Cancer Epidemiol Biomarkers Prev. 6:1997;93-98.
101. Watanabe M., Fukutome K., Murata M.et al. Significance of vitamin D receptor gene polymorphism for prostate cancer risk in Japanese. Anticancer Res. 19:1999;4511-4514.
102. Feigelson H.S., Ross R.K., Yu M.C., Coetzee G.A., Reichardt J.K.V., Henderson B.E. Genetic susceptibility to cancer from exogenous and endogenous exposures. J Cell Biochem. 25S:1996;15-22.
103. Perera F.P. Molecular epidemiology. insight into cancer susceptibility, risk assessment, and prevention J Natl Cancer Inst. 88:1996;496-509.
104. Wang C.Y., Debiec-Rychter M., Schut H.A.et al. N-Acetyltransferase expression and DNA binding of N-hydroxyheterocyclic amines in human prostate epithelium. Carcinogenesis. 20:1999;1591-1596.
105. Fukutome K., Watanabe M., Shiraishi T.et al. N-acetyltransferase 1 genetic polymorphism influences the risk of prostate cancer development. Cancer Lett. 136:1999;83-87.
106. Murata M., Shiraishi T., Fukutome K.et al. Cytochrome P4501A1 and glutathione S-transferase M1 genotypes as risk factors for prostate cancer in Japan. Jpn J Clin Oncol. 28:1998;657-660.
107. Rebbeck T.R., Walker A.H., Jaffe J.M., White D.L., Wein A.J., Malkowicz S.B. Glutathione S-transferase-mu (GSTM1) and -theta (GSTT1) genotypes in the etiology of prostate cancer. Cancer Epidemiol Biomarkers Prev. 4pt1:1999;283-287.
108. Febbo P.G., Kantoff P.W., Giovannucci E.et al. Debrisoquine hydroxylase (CYP2D6) and prostate cancer. Cancer Epidemiol Biomarkers Prev. 7:1998;1075-1078.
109. Rebbeck T.R., Jaffe J.M., Walker A.H., Wein A.J., Malkowicz S.B. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst. 90:1998;1225-1229.